Ablynx is a biopharmaceutical company focused on the discovery and development of Nanobodies®, a new class of antibody-derived therapeutics for inflammation, cancer, blood and lung disease.
Ablynx currently has more than 30 products under development in its product pipeline. It collaborates with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Merck & Co, Merck Serono and Novartis. These collaborations have generated over €300 million cash to date. Ablynx is building its own proprietary pipeline consisting of Nanobody® therapeutic programs.
Gilde invested in Ablynx after it was first spun out from the Flemish Institute of Biotechnology (VIB). It also supported the company through all its subsequent financing rounds. In 2007, Ablynx successfully listed at Euronext Brussels (ABLX). The company has since become one of the European pioneers in biopharmaceuticals.